Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD protein from NKMAX Co. Ltd.
Search, find, compare suppliers for Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD protein products.
| Edit | |
|---|---|
| Product Name | Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD protein |
| Description | Domain: 319-541aa. Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques. MW: 26.2kDa (232aa). Purity > 95% by SDS-PAGE. An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). This virus shares highly homological sequence with SARS-CoV, and causes acute, highly lethal pneumonia coronavirus disease 2019 (COVID-19) with clinical symptoms similar to those reported for SARS-CoV and MERS-CoV. The genome of this and other emerging pathogenic human CoVs encodes four major structural proteins [spike (S), envelope (E), membrane (M), and nucleocapsid (N)], approximately 16 nonstructural proteins (nsp1-16), and five to eight accessory proteins. Among them, the S protein plays an essential role in viral attachment, fusion, entry, and transmission. It comprises an N-terminal S1 subunit responsible for virus-receptor binding and a C-terminal S2 subunit responsible for virus-cell membrane fusion. S1 is further divided into an N-terminal domain (NTD) and a receptor-binding domain (RBD). SARS-CoV-2 and SARS-CoV bind angiotensin-converting enzyme 2 (ACE2) while MERS-CoV binds dipeptidyl peptidase 4 (DPP4), as receptors on the host cell expressing ACE2 (e.g., pneumocytes, enterocytes) or DPP4 (e.g., liver or lung cells including Huh-7, MRC-5, and Calu-3). During infection, CoV first binds the host cell through interaction between its S1-RBD and the cell membrane receptor, triggering conformational changes in the S2 subunit that result in virus fusion and entry into the target cell |
| Size | 10ug, 20ug, 50ug, 100ug, 250ug, 500ug, 1mg |
| Concentration | 0.25mg/ml (determined by Absorbance at 280nm) |
| Applications | SDS-PAGE, Bioactivity |
| Other Names | Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 virus, COVID19, HCoV-19, Human coronavirus 2019, SARS-2, SARS-CoV2, SARS2, Wuhan coronavirus, SARS-CoV-2 SP RBD, 2019-nCoV SP RBD, 2019-nCoV, 2019-nCoV; Spike RBD Protein |
| Gene, Accession, CAS # | NCBI: QHD43416.1, UniProt: P0DTC2 |
| Catalog # | ATGP3962 |
| Price | $108, $198, $261, $432, $765, $1305, $2178 |
| Order / More Info | Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD protein from NKMAX Co. Ltd. |
| Product Specific References | Yoon W, et al. Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2. (Vaccines (Basel). 2022){https://pubmed.ncbi.nlm.nih.gov/35062728/} |
NKMAX Co. Ltd.
NKMAX Co. Ltd.
6F, SNUH Health Care Innovation Park
172 Dolma-ro, Bundang-gu
Seongnam-si, Gyeonggi-do 13605 REPUBLIC OF KOREA
P: +82-31-8017-8114
F: +82-31-8017-8124
salesbio@nkmax.com
http://www.nkmaxbio.com
Profile of NKMAX Co. Ltd.
Return to Products